MMTZFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as RLFTY
MindMaze Therapeutics Holding SA
Financials through fiscal 2023, year ended Dec 31, 2023Last filing: 20-F on Apr 30, 2024
$0.19−0.00 (-0.22%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2020 to 2023
Operating margin
-1751.4%
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -11.0% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2023 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 2.65 | |
| Net debt to EBITDA | – | – | 0.13× | |
| Interest coverage | – | – | -116.8× | |
| Capex to revenue | – | – | 7.0% | |
| Diluted shares | – | – | 12M |
Cash use needs five years of cash flow figures
MindMaze Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
2of 5 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-CHF 17.61M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CHF 17.61M vs –
- Less leverageLong-term debt to assets fell0.0% → 0.0%
- Better liquidityCurrent ratio rose2.11 → 2.65
- No dilutionShare count did not rise11M → 12M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.03 → 0.03